Every round on record, with the sources behind each and the investors on them.
A medical technology company applying artificial intelligence (AI) to oculomics and the detection and management of eye disease
cascader.aiLinkedInLondon, UKHealthtech
12 sources · checked 1 time, last 42d ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source states no amount, valuation, headquarters, or additional investors for the round. London is the article dateline, not a stated headquarters.; not on the page it cites, so not applied: date
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | n/a | 2026-09-22 | Topcon Healthcare | No recent discussion |
12 sources · checked 1 time, last 42d ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 12 sources
The source states no amount, valuation, headquarters, or additional investors for the round. London is the article dateline, not a stated headquarters.; not on the page it cites, so not applied: date | ||||
Cascader builds AI-powered tools that help clinicians in hospitals and primary care detect and manage eye disease and use retinal imaging to reveal wider health risks.
Cascader is addressing the clinical and operational challenge of turning advanced retinal imaging and oculomics research into safe, evidence-based tools that enable earlier diagnosis and treatment of macular and other diseases, potentially helping prevent avoidable sight loss. Its September 2026 seed round, led by Topcon Healthcare, is intended to move its initial products toward market launch, expand the team, and translate more than a decade of Moorfields and UCL research into scalable clinical care.
Checked against 10 sources on Sep 23